Clarity Medical Group Holding Limited submitted its monthly return for the period ending 31 May 2026, confirming that authorised share capital and issued share capital remained unchanged during the month.

The company’s authorised share capital stood at 5.00 billion ordinary shares with a par value of HKD 0.01, equivalent to HKD 50.00 million. Issued shares (excluding treasury shares) were steady at 536.33 million, with no movement in either issued or treasury shares throughout the month. Consequently, total issued shares remained at 536.33 million.

The issuer affirmed compliance with Hong Kong’s minimum public-float requirement, maintaining at least 25% of its issued shares in public hands as stipulated under Main Board Rule 13.32B.

No new share options, warrants, or convertible securities were issued, and there were no exercises, cancellations, or transfers involving existing options. The pre-IPO share option scheme shows no outstanding or exercisable options.

Under the company’s share-award plan, last approved at an extraordinary general meeting on 23 November 2022, up to 43.97 million shares remain available for future grants. No new shares were awarded or transferred during May 2026.

All requisite confirmations regarding compliance with Hong Kong Listing Rules, receipt of funds, and regulatory filings were provided by Executive Director Jiang Bo in the submission dated 3 June 2026.